Number (n = 25) | (%) | |
---|---|---|
Age | ||
Adult | 18 | (72.0) |
Child | 7 | (28.0) |
Hospital Acquired | 25 | (100) |
Clinical Unit | ||
Adult Oncology | 11 | (44.0) |
Paediatric Oncology | 5 | (20.0) |
Intensive Care Unit+ | 3 | (12.0) |
Renal Dialysis Unit | 4 | (16.0) |
Neonatal Intensive Care | 1 | (4.0) |
Paediatric Medical | 1 | (4.0) |
Underlying Disease | ||
Malignancy | 19 | (76.0) |
End stage renal failure | 4 | (16.0) |
Prematurity | 1 | (4.0) |
End stage respiratory failure | 1 | (4.0) |
Immunocompromised | 25 | (100) |
Source | ||
Line-associated | 22 | (88.0) |
Febrile neutropenia | 1 | (4.0) |
Pneumonia | 1 | (4.0) |
Skin soft tissue infection | 1 | (4.0) |
Polymicrobial | 9** | (36.0) |
Treatment of line infection | ||
Line removal | 11/12* | (91.7) |
Antimicrobial therapy | ||
Cotrimoxazole | 14/16* | (87.5) |
Outcome | ||
Death | 2 | |
Death attributed to S. maltophilia | 0 |